Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two selective serotonin reuptake inhibitors (SSRIs): citalopram and escitalopram. Citalopram is a racemic mixture containing both R- and S-enantiomers, while escitalopram consists solely of the S-enantiomer, which is considered the pharmacologically active component. Both drugs function by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability and enhancing serotonergic neurotransmission. They are primarily indicated for major depressive disorder and generalized anxiety disorder, with additional off-label uses including panic disorder, obsessive-compulsive disorder (OCD), and social anxiety disorder[3][4][5][6][7]. The combination of these two agents in a single formulation or regimen is not standard clinical practice due to their overlapping mechanisms; typically only one would be prescribed at a time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citalopram + escitalopram.